NUF2 promotes the malignant development of lung adenocarcinoma through the mTORC1 signaling pathway via binding to BUB1B

NUF2 drives LUAD progression via BUB1B-mediated mTORC1 activation. Targeting the NUF2/BUB1B axis may offer a promising therapeutic strategy to mitigate LUAD malignancy. These findings provide critical insights into the molecular underpinnings of LUAD and highlight potential pathways for clinical intervention.